We are live on ! Find out more
OM icon

Outset Medical

94 hedge funds and large institutions have $352M invested in Outset Medical in 2025 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 25 increasing their positions, 15 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

413% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 8

116% more capital invested

Capital invested by funds: $163M → $352M (+$189M)

110% more call options, than puts

Call options by funds: $915K | Put options by funds: $436K

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

67% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 15

54% more funds holding

Funds holding: 6194 (+33)

22.32% more ownership

Funds ownership: 83.23%105.55% (+22%)

Holders
94
Holders Change
+33
Holders Change %
+54.1%
% of All Funds
1.24%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
41
Increased
25
Reduced
15
Closed
8
Calls
$915K
Puts
$436K
Net Calls
+$479K
Net Calls Change
+$802K
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$50M +$55K +3,524 +0.1%
PHS
2
PFM Health Sciences
California
$32M -$328K -21,000 -1%
DCP
3
Durable Capital Partners
Maryland
$31.8M -$1.3M -83,090 -5%
T. Rowe Price Investment Management
4
T. Rowe Price Investment Management
Maryland
$31.2M +$320K +20,480 +1%
Alyeska Investment Group
5
Alyeska Investment Group
Illinois
$28.1M -$3.72M -238,501 -14%
WP
6
Woodline Partners
California
$25.5M
Vanguard Group
7
Vanguard Group
Pennsylvania
$19M +$12.8M +818,104 +472%
BlackRock
8
BlackRock
New York
$18.9M +$14.3M +917,973 +1,393%
PA
9
Perceptive Advisors
New York
$16M
Massachusetts Financial Services
10
Massachusetts Financial Services
Massachusetts
$12.2M -$3.18M -203,915 -24%
PHP
11
Parkman Healthcare Partners
Connecticut
$10.5M +$4.96M +317,953 +138%
Marshall Wace
12
Marshall Wace
United Kingdom
$10M -$2.01M -128,864 -20%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$7.98M +$5.87M +376,196 +956%
Ensign Peak Advisors
14
Ensign Peak Advisors
Utah
$6.04M +$3.59M +230,065 +272%
SSA
15
Schonfeld Strategic Advisors
New York
$4.93M +$1.04M +66,526 +35%
Northern Trust
16
Northern Trust
Illinois
$4.79M +$3.89M +249,358 New
State Street
17
State Street
Massachusetts
$3.94M +$2.96M +189,809 +1,228%
CCM
18
Catalio Capital Management
New York
$3.2M
Millennium Management
19
Millennium Management
New York
$3.05M +$679K +43,474 +38%
Balyasny Asset Management
20
Balyasny Asset Management
Illinois
$2.75M +$2.23M +143,160 New
Bank of America
21
Bank of America
North Carolina
$2.61M +$2.12M +135,525 +37,130%
Morgan Stanley
22
Morgan Stanley
New York
$2.33M +$885K +56,676 +88%
GC
23
GMT Capital
Georgia
$1.88M
Goldman Sachs
24
Goldman Sachs
New York
$1.77M +$1.44M +92,122 New
UBS Group
25
UBS Group
Switzerland
$1.53M +$1.05M +67,485 +558%

OM Hedge Fund Activity: Q2 2025 in Review

94 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Outset Medical (OM) for Q2 2025, worth a combined $352M — up 116% from $163M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new OM positions and 8 closed out — a net gain of 33 holders — while 25 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $14.3M. The largest seller was Alyeska Investment Group, cutting an estimated $3.72M.

  • 94 institutional investors held Outset Medical (OM) as of Q2 2025, up from 61 in Q1 2025.
  • Funds reported $352M of Outset Medical stock for Q2 2025, up 116% quarter-over-quarter.
  • 41 funds opened new Outset Medical positions in Q2 2025 and 8 closed out, a net change of +33 holders.
  • The largest Outset Medical buyer in Q2 2025 was BlackRock, an estimated $14.3M added.
  • The largest Outset Medical seller in Q2 2025 was Alyeska Investment Group, an estimated $3.72M sold.

Based on aggregated 13F filings for Q2 2025.